Peptides & the FDA review: your questions, answered

No. Removal from Category 2 in April 2026 did not add BPC-157 to the approved Category 1 list. It moved the peptide into a review process, not into approval.^{1 2}

On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviews seven peptides, hears presentations and public comment, and votes a recommendation on whether each should be added to the 503A bulks list. The vote is advisory; the FDA makes the final call afterward.³

No. BPC-157 has not been approved by the FDA for any medical use, and most of the published research is from animal studies rather than large human trials.⁴

BPC-157 is not an FDA-approved drug and is not a lawful dietary ingredient. It was placed in Category 2 of the interim 503A compounding list in September 2023, then removed from that category in April 2026 and referred to an advisory committee. As of July 2026, no final rule has placed it on the approved 503A bulks list, so it has no cleared legal pathway for compounding.^{5 1 6}